HanchorBio to Present Five Clinical Abstracts at CSCO 2026, Including Two Oral Presentations for Lead Program HCB101
Clinical data strengthen HCB101 as a differentiated CD47–SIRPα backbone and support expansion across gastric cancer, HNSCC, and additional solid tumors
TAIPEI, SHANGHAI, and SAN FRANCISCO — September 18, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026), taking place September 17–19, 2026, in Jinan, China.
Two HCB101 abstracts were selected for oral presentation, highlighting the progression of HanchorBio’s lead macrophage-directed immunotherapy from first-in-human monotherapy validation to combination activity in second-line gastric/gastroesophageal junction (GC/GEJ) cancer. HCB301 was selected for poster presentation, alongside additional HCB101 presentations in head and neck squamous cell carcinoma (HNSCC) and gastrointestinal cancers.
The accepted abstracts demonstrate HCB101’s transition from initial proof-of-concept toward a broadly usable macrophage-directed backbone across multiple indications and standard-of-care regimens, while HCB301 extends the Company’s platform into multi-axis immunotherapy.
“The selection of two oral presentations for HCB101 at CSCO demonstrates that our clinical strategy extends beyond fundamental CD47 biology,” said Scott Liu, PhD, Founder and Chairman of HanchorBio. “We have established a robust clinical safety foundation, demonstrated meaningful combination activity in gastric cancer, and captured positive expansion signals across additional tumor types. As HCB101 combines across multiple standard-of-care regimens, its opportunity expands well beyond a single-indication asset—creating multiple paths to long-term clinical and commercial value.”
HCB101 Monotherapy Establishes the Clinical Foundation
The first oral presentation will summarize the completed Phase 1a HCB101-101 study (NCT05892718).
Among 67 treated patients, dose escalation reached 36 mg/kg without reaching the maximum tolerated dose. Across 59 DLT-evaluable patients, HCB101 demonstrated a differentiated hematologic safety profile, including one Grade 3 anemia event, no Grade 4–5 anemia events, and no bleeding events associated with thrombocytopenia, alongside predictable pharmacokinetics and sustained CD47 receptor occupancy.
Across 56 efficacy-evaluable patients, HCB101 monotherapy produced two confirmed partial responses and 11 stable disease outcomes, yielding a disease control rate (DCR) of 23%. A confirmed partial response in HNSCC remains ongoing beyond 83 weeks, supporting durable monotherapy proof of biology.
These findings establish the safety, exposure, and target-engagement profile required to combine HCB101 with standard-of-care anticancer therapies across broader oncology indications.
Second-Line Gastric/GEJ Cancer Shows the Strongest Combination Signal
The second oral presentation will report updated results from HCB101-201 (NCT06771622), evaluating HCB101 in combination with ramucirumab and paclitaxel in second-line advanced GC/GEJ cancer.
Among 15 efficacy-evaluable patients, the overall objective response rate (ORR) was 60%, highlighted by an 80% ORR in the 5.12–8 mg/kg mid-dose cohorts with a maximum tumor reduction of −78.2%.
For historical context, standard-of-care ramucirumab plus paclitaxel yielded ORRs of approximately 26–28% in the landmark RAINBOW and RAINBOW-Asia trials. While cross-trial comparisons are inherently limited and randomized trials remain required, the magnitude and consistency of tumor shrinkage support second-line GC/GEJ as a primary development path for HCB101. Adding HCB101 to an established global regimen provides a streamlined route toward randomized trials and potential clinical adoption.
Expansion into HNSCC and Multi-Axis Immunotherapy Pipeline
Additional presentations will detail HCB101’s activity in HNSCC and gastrointestinal cancers. In HNSCC, HanchorBio will present durable monotherapy responses alongside emerging combination activity, including a complete response and confirmed partial response from an investigator-initiated study in Taiwan. Evaluation of sponsor-led HNSCC cohorts in combination with PD-1- and EGFR-directed therapies remains ongoing.
HCB301, HanchorBio’s trispecific SIRPα–PD-L1–TGFβ fusion protein, was selected for poster presentation. Updated first-in-human data from the Phase 1 study (NCT06487624) across 29 treated patients (21 efficacy-evaluable) demonstrated an overall DCR of 38.1% and a 75% DCR at 1.2 mg/kg, with disease stabilization observed across multiple solid tumor types.
“CSCO highlights HCB101 as the clinical anchor of our platform,” said Alvin Luk, PhD, MBA, CCRA, President and Chief Medical Officer (Group) & CEO (USA) of HanchorBio. “Monotherapy confirmed that HCB101 is pharmacologically active and well-tolerated. Gastric cancer demonstrates how this biology enhances established standard-of-care regimens, while HNSCC and GI data show its broad applicability. Simultaneously, HCB301 extends this foundation into multi-axis immunotherapy, addressing innate suppression, adaptive checkpoints, and TGFβ exclusion within a single molecule.”
One clinical anchor. Multiple indications. Multiple treatment backbones. A broader platform.
HCB101 is establishing the clinical foundation. HCB301 and the broader FBDB™ pipeline extend the opportunity.
About HCB101
HCB101 is an investigational engineered SIRPα–IgG4 Fc fusion protein developed using HanchorBio’s FBDB™ platform. HCB101 blocks CD47–SIRPα signaling to restore macrophage-mediated antitumor immunity and downstream de novo T-cell activation. It is being evaluated as monotherapy (NCT05892718) and in combination (NCT06771622) across solid and hematologic malignancies and holds U.S. FDA Orphan Drug Designation for gastric cancer.
About HCB301
HCB301 is an investigational trispecific CD47–PD-L1–TGFβ fusion protein designed to concurrently address innate immune suppression, adaptive checkpoint signaling, and TGFβ-mediated immune exclusion within a single molecule. It is being evaluated in the ongoing first-in-human Phase 1 HCB301-101 study (NCT06487624).
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on inventing next-generation biologics for cancer and immune-mediated diseases using its proprietary FBDB™ platform. HanchorBio’s pipeline includes clinical-stage programs HCB101 and HCB301, alongside additional candidates across oncology and immunology.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical trial outcomes, regulatory decisions, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
Investor & Media Contact:
HanchorBio, Inc.
Email: [email protected]